|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500107563 |
|
最近更新日期: Date of Last Refreshed on: |
2025-08-14 08:41:35 |
|
注册时间: Date of Registration: |
2025-08-14 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
剖宫产术中应用艾司氯胺酮与右美托咪定对产妇出血量及血流动力学的影响 |
|
Public title: |
The Effects of Escloramfetamine and Dexmedetomidine on Maternal Blood Loss and Hemodynamic Parameters During Cesarean Section |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
剖宫产术中应用艾司氯胺酮与右美托咪定对产妇出血量及血流动力学的影响 |
|
Scientific title: |
The Effects of Escloramfetamine and Dexmedetomidine on Maternal Blood Loss and Hemodynamic Parameters During Cesarean Section |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
邓春云 |
研究负责人: |
王涛 |
|
Applicant: |
Chunyun Deng |
Study leader: |
Tao Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 138 7647 6483 |
研究负责人电话:
Study leader's |
+86 137 3318 8632 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
dengcy2000@163.com |
研究负责人电子邮件: Study leader's E-mail: |
dengcy2000@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河南省郑州市二七区康复前街7号 |
研究负责人通讯地址: |
河南省郑州市二七区康复前街7号 |
|
Applicant address: |
No.7 ZhengZhou Kangfufront Street, Zhengzhou 450052, Henan Provimce, China |
Study leader's address: |
No.7 ZhengZhou Kangfufront Street, Zhengzhou 450052, Henan Provimce, China |
|
申请注册联系人邮政编码: Applicant postcode: |
450052 |
研究负责人邮政编码: Study leader's postcode: |
450052 |
|
申请人所在单位: |
郑州大学第三附属医院 |
||
|
Applicant's institution: |
The Third Affiliated Hospital of ZhengZhou University |
||
|
研究负责人所在单位: |
郑州大学第三附属医院 |
||
|
Affiliation of the Leader: |
The Third Affiliated Hospital of ZhengZhou University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-360-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
郑州大学第三附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Third Affiliated Hospital of Zhengzhou University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-10-31 00:00:00 | ||
|
伦理委员会联系人: |
李兵兵 |
||
|
Contact Name of the ethic committee: |
Bingbing Li |
||
|
伦理委员会联系地址: |
河南省郑州市二七区康复前街7号 |
||
|
Contact Address of the ethic committee: |
No.7, Zhengzhou Kangfufront Street, Zhengzhou 450052, Henan Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 371 6690 3015 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
郑州大学第三附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Third Affiliated Hospital of ZhengZhou University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
河南省郑州市二七区康复前街7号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.7 ZhengZhou Kangfufront Street, Zhengzhou 450052, Henan Provimce, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
郑州大学第三附属医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
The Third Affiliated Hospital of ZhengZhou University |
||||||||||||||||||||||
|
研究疾病: |
剖宫产术中出血量 |
||||||||||||||||||||||
|
Target disease: |
Blood loss during cesarean section |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
剖宫产术中最重要的并发症是术中出血,手术出血量的多少严 重影响产妇的预后及新生儿健康,如术中出血过多可造成产妇机体 免疫力下降,产褥期感染的风险也将大大增加,因此研究剖宫产术 中出血的相关联因素并实施对应举措具有非常重要的临床实用价值。 椎管内麻醉是一种广泛用于剖宫产的麻醉技术。由于剖腹产期 间常有腹腔神经未完全阻滞的情况,一些产妇在子宫探查、牵拉腹 膜和胎儿分娩过程中会感到不适或疼痛。因此,在使用椎管内麻醉 进行剖腹产时,经常需要给予额外的补充镇痛药物。有研究表明, 麻醉药物可能是剖宫产术中出血的影响因素。 |
||||||||||||||||||||||
|
Objectives of Study: |
The most critical complication during cesarean section is intraoperative bleeding, and the extent of blood loss during surgery significantly affects the mother's prognosis and the newborn's health. Excessive intraoperative bleeding can lead to a decline in the mother's immune function and a significantly increased risk of postpartum infection. Therefore, studying the associated factors of intraoperative bleeding during cesarean section and implementing corresponding measures holds significant clinical practical value. Epidural anesthesia is a widely used anesthetic technique for cesarean section. During cesarean section, there is often incomplete blockage of abdominal nerves, causing some mothers to experience discomfort or pain during uterine exploration, peritoneal traction, and fetal delivery. Therefore, when using spinal anesthesia for cesarean section, additional supplementary analgesic medications are often required. Studies have shown that anesthetic drugs may be a contributing factor to bleeding during cesarean section. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1) 美国麻醉医师协会身体状况 ASA分级 II; (2)年龄在20-40 岁之间; (3)怀孕 37-42 周; (4)体重指数≤35 kg/m2。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) American Society of Anesthesiologists (ASA) physical status classification II; (2) Age between 20 and 40 years old; (3) Pregnancy between 37 and 42 weeks; (4) Body mass index (BMI) <= 35 kg/m^2. |
||||||||||||||||||||||
|
排除标准: |
(1)紧急剖宫产;(2)脊髓麻醉禁忌症(凝血异常、腰椎间盘突出、脊柱畸形或手术史);(3)双胞胎妊娠;(4)对α过敏 2-肾上腺素能激动剂或阿片类药物;(5)术前使用镇痛药或镇静剂;(6)无法理解本试验中使用的各种量表;(7)神经系统或精神疾病;或 (8) 纳入其他临床试验。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Emergency cesarean section; (2) Contraindications for spinal anesthesia (coagulation disorders, lumbar disc herniation, spinal deformities, or history of spinal surgery); (3) Twin pregnancy; (4) Allergy to α2-adrenergic agonists or opioid medications; (5) Preoperative use of analgesics or sedatives; (6) Inability to understand the various scales used in this trial; (7) Neurological or psychiatric disorders; or (8) Enrollment in other clinical trials. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-11-01 00:00:00至 To 2025-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-11-07 00:00:00 至 To 2025-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究者运用excel软件生成随机数字表,并将随机数字分组并记录。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Researchers used Excel software to generate random number tables, grouped the random numbers, and recorded them. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲:患者对分组情况不知情,研究者对研究情况之情。 |
|
Blinding: |
Single-blind: Patients are unaware of the grouping, while researchers are aware of the study details. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2026-06-20 国家生物信息中心 https://ngdc.cncb.ac.cn/gsub/ |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
2026-06-20 China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病历记录后交由科室负责人统一管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
After the medical records are recorded, they will be handed over to the head of the department for unified management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |